<DOC>
	<DOCNO>NCT00103272</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin bortezomib treat patient relapsed refractory hematologic cancer . Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving 17-N-allylamino-17-demethoxygeldanamycin together bortezomib may kill cancer cell .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Bortezomib Treating Patients With Relapsed Refractory Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) PS-341 ( Velcade , Bortezomib ) combination 17-allyamino-17-demethoxygeldanamycin ( 17-AAG ) patient relapse refractory acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) . II . To determine MTD PS-341 combination 17-AAG patient relapse refractory chronic lymphocytic leukemia ( CLL ) , non-Hodgkin 's lymphoma ( NHL ) . III . To define specific toxicity dose limit toxicity ( DLT ) PS-341 combination 17-AAG treatment patient relapse refractory hematologic malignancy . SECONDARY OBJECTIVES : I . To determine pharmacokinetics 17-AAG alone combination PS-341 patient AML , ALL , CLL , NHL . II . To evaluate 20S proteasome inhibition follow combination therapy 17-AAG PS-341 patient AML , ALL , CLL , NHL . III . To assess relationship FLT3 mutational status leukemic cell response PS-341 17-AAG patient AML . IV . To assess relationship Bcl-2 over-expression response 17-AAG PS-341 patient AML NHL . V. To evaluate effect combination PS-341 17-AAG Hsp90 NF-kappaB downstream target include Hsp70 , Akt , phosphorylated Akt , p21 , caspases 3 9 patient-derived primary AML NHL cell . OUTLINE : This dose-escalation study . Patients stratify accord diagnosis ( acute myeloid leukemia [ AML ] acute lymphoblastic leukemia v chronic lymphoctyic leukemia non-Hodgkin 's lymphoma [ NHL ] ) . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) intravenously ( IV ) 1-6 hour day 1 , 4 , 8 , 11 bortezomib IV 3-5 second day 4 , 8 , 11 course 1 day 1 , 4 , 8 , 11 subsequent course . Treatment repeat every 21 day 3-12 course provide patient receive clinical benefit . Patients achieve objective response may discontinue therapy undergo stem cell transplantation.Cohorts 3-6 patient receive escalate dos 17-AAG bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After MTD determine , additional 20 patient ( 10 per stratum AML follicular NHL ) enrol receive 17-AAG bortezomib MTD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia acute lymphoblastic leukemia Not candidate potentially curative therapy WBC ≤ 10,000/mm^3 OR WBC ≤ 40,000/mm^3 stable 5 day ( hydroxyurea allow ) No acute promyelocytic leukemia NonHodgkin 's lymphoma ( NHL ) , include 1 follow subtypes : Small lymphocytic lymphoma Marginal zone lymphoma Lymphoplasmacytic lymphoma Follicular lymphoma Mantle cell lymphoma Diffuse large Bcell lymphoma Anaplastic large cell lymphoma Peripheral Tcell lymphoma Extranodal NK/T cell lymphoma ( nasal nasal type ) Enteropathytype Tcell lymphoma Hepatosplenic Tcell lymphoma Angioimmunoblastic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Chronic lymphocytic leukemia ( CLL ) Patients NHL CLL must meet following criterion : Ineligible , refuse potentially curative stem cell transplantation Transformed lymphoma/Richter 's transformation , define transformation lowgrade lymphoma , include follicular lymphoma , CLL , small lymphocytic lymphoma highgrade lymphoma ( i.e. , diffuse large cell lymphoma ) allow time transformation Evidence ≥ 50 % bone marrow involvement time enrollment OR tumor tissue accessible biopsy ( patient enrol maximum tolerate dose [ MTD ] determine ) Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Relapsed refractory disease Willing undergo serial bone marrow biopsy ( patient enrol MTD determine ) No untreated active CNS leukemia lymphoma Performance status ECOG 02 At least 12 week Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 2.0 mg/dL No uncontrolled cardiac disease No New York Heart Association class IIIIV symptomatic congestive heart failure No unstable angina pectoris No serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation &gt; 3 beat row ) within past 6 month No uncontrolled cardiac arrhythmia require antiarrhythmic drug No myocardial infarction within past year No active ischemic heart disease within past year No congenital long QT syndrome No leave bundle branch block QTc ≥ 450 msec ( men ) 470 ( woman ) ECG/EKG No history LVEF &lt; 50 % MUGA echocardiogram Resting ejection fraction ≥ 50 % MUGA echocardiogram No prior history cardiac toxicity receive anthracycline therapy ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride ) No uncontrolled pulmonary disease No symptomatic pulmonary disease require oxygen medication DLCO ( i.e. , oxygen diffusion capacity ) ≥ 80 % pulmonary function test Resting exercise oxygen saturation ≥ 90 % pulse oximetry No ongoing pulmonary symptom ≥ grade 2 include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Significant pulmonary disease include chronic obstructive restrictive pulmonary disease No prior history pulmonary toxicity bleomycin carmustine No Medicare requirement home oxygen ( e.g. , Resting O_2 saturation ≥ 90 % desaturation ≥ 90 % exertion ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No preexist sensory motor peripheral neuropathy ≥ grade 2 No history allergic reaction egg No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness Prior stem cell transplantation relapse refractory disease allow At least 2 week since prior immunotherapy recover At least 2 week since prior chemotherapy ( exclude hydroxyurea ) recover No concurrent chemotherapy No concurrent routine corticosteroid except treatment medical problem ( e.g. , pulmonary , rheumatologic , adrenal disorder ) At least 2 week since prior radiotherapy recover No prior radiotherapy potentially include heart field ( e.g. , mantle ) No prior history chest radiation No concurrent palliative radiotherapy At least 2 week since prior investigational therapy Prior bortezomib allow No concurrent commercial investigational agent therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>